GL1X · GenesisL1 explorer

MolNFT v1 · #159490 · protein

Human liver receptor homolog-1 bound to the agonist 5N and a fragment of the TIF2 coregulator

6OQX · Nuclear receptor subfamily 5 group a member 2: “Human liver receptor homolog-1 bound to the agonist 5N and a fragment of the TIF2 coregulator”. X-ray diffraction, 1 ligand (N1V), 3 pockets (best druggability 0.85). MolNFT v1 #159490…

PDB
6OQX
Type
protein
Length
250 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Nuclear receptor subfamily 5 group a member 2; Nuclear receptor coactivator 2
UniProt
O00482, Q15596
Ligands
N1V
Pockets
3 · best druggability 0.85

Structure

x-ray diffraction · 2 distinct chains · 73% helix, 2% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ANuclear receptor subfamily 5 group a member 2protein23973% helix, 3% strandO00482
CNuclear receptor coactivator 2protein1173% helix, 0% strandQ15596

Ligands and binding sites

  • N1V · (8beta,11alpha,12alpha)-8-(1-phenylethenyl)-1,6:7,14-dicycloprosta-1,3,5,7(14)-tetraen-11-yl sulfamate · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13880.850.9334N1V
21080.540.8321empty
3510.290.7515empty

Interfaces

1 interface between chains.

  • A–C · 596 Ų buried · 6 hydrogen bonds · protein-protein

Compared structures

  • 6OQX · Human Liver Receptor Homolog-1 bound to the agonist 5N and a fragment of the Tif2… · the same entry in another collection · chain A against A, TM-score 1.00
  • O00482 · AlphaFold monomer V2.0 prediction for nuclear receptor subfamily 5 group a member 2… · a predicted model of the same protein · chain A against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.